New protein function could explain cause of neurological disease

Linking actin bundling to Charcot-Marie-Tooth Disease

Banner image: Time-lapse image showing free actin filaments (left) gradually being organized into bundles and cables by the tyrosyl-tRNA synthetase.

Antwerp, 9 March - The nerves in your body make you move, feel, and think. CMT, or Charcot-Marie-Tooth disease, is an inherited and incurable neurological disease that occurs in one in every 2500 people. The disorder affects the nerves in your limbs, making it hard to move. More than 100 genes have been linked to CMT, but researchers remain largely in the dark about how these genes could cause the disease. Now, the lab of Albena Jordanova (VIB-UAntwerp Center for Molecular Neurology) sheds light on this. They found that a group of proteins that help build cells also have another job: making tight bundles of actin fibers in the cells. When these proteins don't work correctly, they can damage the nerves and cause the symptoms of CMT. Their work was published in the leading journal Nature Communications.

Albena Jordanova: "Our findings expand the current knowledge of textbook enzymes and provide a new framework on how to explain diseases like CMT. We hope that future studies will build on our research and help develop new treatments for this disease."

The most common rare disease

CMT, or Charcot-Marie-Tooth disease, is an inherited disease that affects nerve cells. Patients usually experience the first symptoms at a younger age, starting in the lower limbs, where muscle strength decreases. They also experience loss of sensation and develop skeletal deformities. CMT affects about 2.5 million people worldwide and around 3500 in Belgium. This makes it the most common rare disease.

More than 100 genes have been implicated in CMT. They are involved in various processes, making it a complicated disease to study. Previously, the group led by Albena Jordanova showed that one class of proteins, tRNA synthetases, are associated with CMT and that defects in these proteins could cause nerve damage in CMT by interfering with the gene transcription in the nucleus. However, how they cause the disease remained unknown. The Jordanova-lab now identified another disease-related function that can be attributed to synthetases and potentially explain CMT and similar neurodegenerative disorders. This discovery is a step forward toward a remedy for these diseases.

Albena Jordanova (left) and Biljana Ermanoska (right)
Albena Jordanova (left) and Biljana Ermanoska (right)

A new biological function

Producing proteins is one of the most essential tasks of the cells in your body, and tRNA synthetases play a significant role. These proteins ensure the correct building blocks are stacked onto a growing protein as it is made. They are constantly at work in every cell of the body. Mutations in these tRNA synthetases are associated with CMT, but strangely enough, they hardly disrupt this essential "block-building" function. This led Jordanova's team to suspect another function of these synthetases.

The researchers discovered that tRNA synthetases don't just build proteins but also make tight bundles of the actin fibers present in cells. These fibers are part of the cell's cytoskeleton, defining its shape and motility. Just like tying together multiple strands of rope creates a stronger and more stable structure, bundling actin filaments creates a larger, more robust skeleton structure that can support the cell. The problem is that defective synthetases may over-bundle actin filaments, impairing proper nerve function and causing CMT. This interference was found in both fruit flies and human cells. Excitingly, modulating the neuronal actin cytoskeleton improves the symptoms of sick flies. This supports the hypothesis that the actin cytoskeleton is involved in CMT, which may have tremendous therapeutic implications for patients.

Biljana Ermanoska, first author of the study, concludes: "Studying essential proteins comes with numerous challenges, which we tackled by adopting interdisciplinary approaches supported by the international teams of collaborators. I am excited to see future studies that will build on our findings and potentially bring together synthetases, actin dynamics, protein translation, and neurodegeneration."

Publication

Tyrosyl-tRNA synthetase has a non-canonical function in actin bundling. Ermanoska, et al. Nature Communications, 2023. DOI/10.1038/s41467-023-35908-3


Questions from patients 

A breakthrough in research is not the same as a breakthrough in medicine. The realizations of VIB researchers can form the basis of new therapies, but the development path still takes years. This can raise a lot of questions. That is why we ask you to please refer questions in your report or article to the email address that VIB makes available for this purpose: patienteninfo@vib.be. Everyone can submit questions concerning this and other medically-oriented research directly to VIB via this address.

About the VIB-UAntwerp Center for Molecular Neurology

Neurodegenerative diseases such as Alzheimer's, epilepsy, and neuromuscular disorders are a major challenge for our society. Research at the VIB-UAntwerp Center for Molecular Neurology begins by studying patients and their family members in order to gain new insights into how these diseases start and develop. Thanks to this knowledge, new therapies can be developed.


India Jane Wise

India Jane Wise

Science Communications Expert, VIB
Joran Lauwers

Joran Lauwers

Press Contact, VIB

Read more

Website preview
The woman and science behind an incurable disease
An interview with a patient and the researchers studying her disease
blog.vib.be

 

 

Share

Latest stories

An inside look at a molecular switch that triggers inflammation

An inside look at a molecular switch that triggers inflammation

Ghent, 9 November 2026 – Researchers at VIB and Ghent University have uncovered how an important driver of inflammation is activated at the molecular level. Their findings, published in Science Immunology, also explain how a medicine used to treat a severe form of psoriasis blocks this inflammatory signal.

press.vib.be

Researchers uncover why humans are more sensitive than other species to a brain developmental disease

Researchers uncover why humans are more sensitive than other species to a brain developmental disease

Leuven, 4 November 2026 – Researchers at VIB and KU Leuven have uncovered how mutations in the ASPM gene disrupt the development of neural stem cells that help the human brain grow. This disruption explains how these mutations cause microcephaly, a condition characterized by an abnormally small brain and head, often accompanied by intellectual disability. The discovery, published in Developmental Cell, also sheds light on how differences in brain development can make humans more susceptible to certain genetic conditions than other mammals.

press.vib.be

How blocking immune cell signals could make brain tumors easier to remove

How blocking immune cell signals could make brain tumors easier to remove

Leuven, Belgium, 27 October 2026 – In a new study published in Cancer Cell, researchers at VIB-KU Leuven reduced the spread of glioblastoma by interrupting specific interactions between the brain’s immune cells and tumor cells. The discovery points to a possible new therapeutic strategy, in which blocking communication between immune and cancer cells makes tumors more contained and easier to remove.

press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be